Neurology
Moyamoya Disease
5
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Moyamoya disease is an early-stage landscape with 5 programs across 1 company. The most active players are Bayer. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 11
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
6
clinical trials
Completed2 · 33%
Unknown status2 · 33%
Recruiting2 · 33%
Clinical Trials
Trial Activity
6 trials
Treatment of Moyamoya Disease With iPSC-derived Exosomes
Recruiting·—·Phase 1·NCT07065409·9 enrolled
Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
Recruiting·—·N/A·NCT06817434·330 enrolled
The Safety and Efficacy of RIC on Adult Moyamoya Disease
Completed·—·N/A·NCT04012268·30 enrolled
NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
Unknown status·—·Phase 3·NCT04205578·450 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)